Core Viewpoint - The company reported a significant revenue increase of 75.4% year-on-year, reaching 294 million RMB, while narrowing its net loss by 12.6% to 132 million RMB, indicating improved financial performance and operational efficiency [1] Financial Performance - Revenue for the six months ending June 30, 2025, was 294 million RMB, reflecting a year-on-year growth of 75.4% [1] - The net loss was 132 million RMB, which is a 12.6% reduction compared to the previous year [1] - Basic loss per share was 0.17 RMB [1] Product Development and Approvals - The company has successfully commercialized multiple products sourced from Alcon, enhancing its product line and market opportunities [1] - Research and development expenses were 39 million RMB, showing a decrease of 33.6% year-on-year, indicating cost management efforts [1] - The product OT-703 (ILUVIEN) has been approved for real-world research application in Hainan Boao Lecheng International Medical Tourism Pilot Zone [1] - The product OT-802 (a treatment for presbyopia) has received CDE approval for its Phase III clinical trial, highlighting its potential to fill a market gap in China [1] - Six products have received production approval during the reporting period, and the commercialization process is progressing smoothly [1]
欧康维视生物-B发布中期业绩，净亏损1.32亿元，同比收窄12.6%